PET imaging to track prostate cancer changes
Part of Cancer clinical trials.
This study uses special PET scans (up to 4 times) to see how metastatic prostate cancer changes over time. It is for people whose cancer has spread and is still growing after hormone treatments, and who are planning to start chemotherapy or PSMA therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer has spread to at least 3 spots in your body (on bone scan or CT scan).
- Your cancer is still growing despite having low testosterone (from drugs or surgery) and after trying an advanced hormone blocker like enzalutamide, abiraterone, apalutamide, or darolutamide.
- You are medically able to receive chemotherapy (like docetaxel) or PSMA-targeted therapy (a type of precision treatment).
- You have not had another cancer (excluding skin cancer) in the last 5 years.
- You are not currently in a blinded clinical trial where you don't know which treatment you're getting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
This trial tests a new radioactive tracer that may help doctors see and treat prostate cancer that has spread. The tracer attaches to cancer cells so they show up on scans, and may also help guide treatment.
This study uses a special scan (PSMA PET/CT) to see how well a new type of hormone therapy is working in men whose prostate cancer has spread to other parts of the body. The goal is to find out if the scan can help doctors track the cancer's response to treatment over time.
This study uses a special type of imaging scan (PSMA PET) to track how well prostate cancer treatment is working by comparing scans before and after your planned therapy. The goal is to help doctors better understand which treatments work best for your type of cancer.
This study uses a special scan called PET/MR with a prostate-focused tracer to help doctors choose the best next treatment for prostate cancer. It may be most helpful if you are planning major treatment or if your cancer has come back after prior treatment.
This study tests whether two kinds of PET scans, one targeting PSMA and one targeting sugar uptake (FDG), can help doctors better understand advanced prostate cancer. If you have prostate cancer that has spread (metastatic) and still responds to hormone therapy, the scans may help guide your treatment.
Hear when a new mCRPC (Metastatic Castration-resistant Prostate Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.